ATRC News and Press, AtriCure Inc. From 05/08/20

Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)...

Image source: The Motley Fool. AtriCure Inc   (NASDAQ: ATRC) Q1 2020 Earnings Call Apr 29, 2020 , 4:30 p.m. ET Operator Continue reading

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m. Eastern Time on Friday, May 8, 2020, to ...

AtriCure, Inc. (ATRC) Q1 2020 Earnings Conference Call April 29, 2020, 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Michael Carrel - CEO, President & Director Andrew Wade - CFO Conference Call Participants Lilia-Celine Breton Lozada - JPMorgan Chase & ...

AtriCure (NASDAQ: ATRC ): Q1 Non-GAAP EPS of -$0.36 beats by $0.04 ; GAAP EPS of -$0.42 misses by $0.01 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide revenue of $53.2 million – a decrease of 1.4% year over year U.S. revenue of $43.5 million – an increase of 1.1% year over year International revenue of $9.8 million – a decrease of 11.0% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a l...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences. AtriCure will be participating in the Bank ...

The stock market's tumble in mid-March was driven by indiscriminate selling caused by an awakening to the possibility of double-digit unemployment and up to a 30% drop in second quarter gross domestic product ((GDP)), coupled with changes in margin requirements resulting in forced liquidation....

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020. AtriCure will host a conference call ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhyt...